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Abstract: Background Venous thromboembolism (VTE) is a recognized complication in patients with
traumatic brain injury (TBI) and is associated with increased morbidity and mortality. Currently, no
standard exists for optimal timing or a pharmacological agent for VTE prophylaxis (pharmacological
thromboprophylaxis – PTP) in patients with TBI. PTP is often delayed out of fear of causing extension
of intracranial hemorrhage (ICH). The purpose of this study was to report the frequency of VTE and
ICH progression after initiation of PTP with a continuous infusion of unfractionated heparin in patients
with moderate to severe TBI, and to identify risk factors associated with development of VTE. Methods
In this single-center retrospective study, patients with moderate to severe TBI admitted to the ICU of
a Swiss Level I Trauma Center over a three-year period were analyzed. Results In 23 (13%) of the 177
patients included in the study a VTE episode occurred during the hospital stay. ICH progression after
initiation of PTP occurred in 7 (4%) patients. In a multivariable logistic regression model, only the
timing of initiation of PTP was identified as an independent predictor of VTE. Conclusions In this study
population, the risk of developing VTE increased with the delay of initiation of a pharmacological VTE
prophylaxis, while ICH progression after initiation of PTP was a rare event.
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ORIGINAL AND CLINICAL ARTICLES 
Venous thromboembolism (VTE), defined as 
deep vein thrombosis (DVT) and/or pulmonary 
embolism (PE), is a well-recognized complication 
in patients with traumatic brain injury (TBI) due to 
increased venous stasis from paralysis, prolonged 
coma [1–3] and systemic hypercoagulability [4, 5]. 
Approximately 5% of all hospitalized patients de-
velop VTE during their hospital stay. However, for 
patients with TBI, the risk of VTE has been reported 
to vary from 30 to 60% [6–9] and to be associated 
with significant morbidity and mortality [4, 10].
The radiological prevalence of intracranial hem-
orrhage (ICH) among patients with TBI is approxi-
mately 45% [11]. The risk for progression of ICH is 
high, particularly early after injury, above all due to 
a trauma-induced coagulopathy, which affects ap-
proximately one third of all patients with TBI [12] and 
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which is associated with increased mortality risk [13]. 
Furthermore, an estimated 3 to 4% of patients show 
ICH progression following pharmacological VTE pro-
phylaxis (PTP) [14, 15]. Therefore, it remains challeng-
ing to balance the initiation of PTP with the potential 
risk of worsening ICH in this patient population. 
Currently no standard exists on the optimal 
timing and agent of choice for PTP in patients with 
TBI and wide variability in the practice patterns has 
been reported [16]. 
Accordingly, studies attempting to identify pa-
tients with potential benefit from PTP reported con-
flicting results [17–22]. However, as patients with 
different grades of severity of TBI and thus various 
risk profiles were included, interpretation of these 
findings remains difficult. In particular, patients with 
moderate and severe TBI have longer periods of im-
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Abstract
Background: Venous thromboembolism (VTE) is a recognized complication in patients 
with traumatic brain injury (TBI) and is associated with increased morbidity and mor-
tality. Currently, no standard exists for optimal timing or a pharmacological agent for 
VTE prophylaxis (pharmacological thromboprophylaxis – PTP) in patients with TBI. 
PTP is often delayed out of fear of causing extension of intracranial hemorrhage (ICH). 
The purpose of this study was to report the frequency of VTE and ICH progression after 
initiation of PTP with a continuous infusion of unfractionated heparin in patients with 
moderate to severe TBI, and to identify risk factors associated with development of VTE.
Methods: In this single-center retrospective study, patients with moderate to severe TBI ad-
mitted to the ICU of a Swiss Level I Trauma Center over a three-year period were analyzed.
Results: In 23 (13%) of the 177 patients included in the study a VTE episode occurred dur-
ing the hospital stay. ICH progression after initiation of PTP occurred in 7 (4%) patients. 
In a multivariable logistic regression model, only the timing of initiation of PTP was identi-
fied as an independent predictor of VTE.
Conclusions: In this study population, the risk of developing VTE increased with the delay 
of initiation of a pharmacological VTE prophylaxis, while ICH progression after initiation 
of PTP was a rare event.
Key words: venous thromboembolism, traumatic brain injury, intracranial hemor-
rhage, unfractionated heparin. 
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mobilization than patients with mild TBI and hence 
are at higher risk of VTE. Only a few studies have 
analyzed PTP in patients with moderate and severe 
TBI [3, 4, 23, 24], presenting conflicting results con-
cerning the influence of PTP agents on develop-
ment of VTE. 
The present study investigates the timing of PTP 
exposure with a continuous infusion of unfraction-
ated heparin (UFH) on VTE and ICH progression in 
patients with moderate to severe TBI during the 
hospitalization and aims to identify risk factors as-
sociated with development of VTE. 
METHODS 
This non-concurrent cohort study was conduct-
ed in the surgical ICU of the University Hospital 
of Zurich, a level I Trauma Center in Switzerland, 
in compliance with the current version of the Dec-
laration of Helsinki and the national legal and reg-
ulatory requirements, and was approved by the 
local Ethics Committee (KEK-ZH-Nr. 2016–00332). 
The ethics committee waived the requirement for 
written informed consent.
All subjects admitted to the surgical ICU be-
tween 1 January 2012 and 30 June 2015 with a di-
agnosis of TBI (ICD Code S00–S09) were identified 
in the hospital’s electronic database (KISIM, Cistec 
Zurich, Switzerland) containing all relevant informa-
tion about the patients.
Inclusion criteria for this study were: age > 16 
years; diagnosis of blunt TBI classified as moderate 
or severe TBI before sedation and intubation. Pa-
tients with GCS 12–9 were classified as having mod-
erate TBI, and patients with GCS < 8 as having severe 
TBI. A minimum length of stay (LOS) in the ICU of 
48 hours was set arbitrarily to exclude patients with 
initially over-estimated severity and no need of an 
intensified treatment, e.g. due to alcohol or drug in-
fluence at the time of trauma, and patients who died 
before an intensified treatment was implemented. 
Baseline patients’ demographic data, pre-hospital 
data, and severity scores were collected. Baseline de-
mographic data included age, sex, and treatment with 
anticoagulants or antiplatelet agents before trauma. 
Pre-hospital data after TBI referred to hypotension 
(defined as systolic blood pressure < 90 mm Hg), 
hypoxemia (defined as SpO
2
 < 90% without supple-
mental oxygen administration), and pupillary reac-
tivity during the rescue phase. Pupillary reactivity 
was considered pathological if one or both pupils 
presented no response to light. Severity scores in-
cluded GCS before sedation and intubation and in 
particular its motor component (GCS m), which bet-
ter predicts 6-month outcome after TBI [25], Injury 
Severity Score (ISS) [26], and the Abbreviated Injury 
Scale of the head region (AIS-head) [27]. 
Data collected during the ICU stay included 
timing of initiation of PTP (expressed in days after 
trauma), the number of days on mechanical venti-
lation (MV-days, expressed in days), the ICU length 
of stay (LOS, expressed in days), and ICU mortality 
(ICU-mortality).
The Marshall classification [28] of head injury 
was used based on the first computed tomogra-
phy (CT) after trauma. Particularly, the percentages 
of patients with epidural hematoma (EDH) and 
traumatic subarachnoid hemorrhage (tSAH) were 
recorded. We decided to use the Marshall classifi-
cation and to collect data about frequency of EDH 
and tSAH because these parameters are needed to 
calculate the IMPACT score to predict 6-month out-
come [29].
Patients were sedated with propofol and remi-
fentanil, or midazolam and fentanyl. In the case of 
elevated intracranial pressure, after a control head 
CT scan to exclude the need of surgery, the seda-
tion was deepened and, in some cases, barbiturates 
were administered. Furthermore, moderate hyper-
ventilation (PaCO
2
 4.8–5.2 kPa) was allowed. 
Screening for VTE was not routinely performed at 
our ICU. By clinical symptoms and/or signs sugges-
tive of VTE (for intubated and sedated patients, red-
ness, pain, warmth and/or swelling in one extremity), 
or diagnosis of vein thrombosis by ultrasound-guid-
ed insertion of central lines, further investigations 
were performed. VTE was defined as an event of DVT 
and/or PE, verified by either Doppler ultrasonogra-
phy of the extremities, and/or CT pulmonary angi-
ography depending on the patient’s clinical stability 
and the attending physician’s choice. The observa-
tion period was the hospitalization length of stay.
According to our institutional policy, sequential 
pneumatic compressive devices (SCD) (Kendall SCD, 
Covidien) were universally applied to lower extremi-
ties, whenever not contraindicated, until initiation 
of PTP. The decision and timing for initiation of PTP 
were at the discretion of the attending intensivist in 
accordance with the neuro- and trauma surgeons. 
At our institution, a continuous infusion of UFH of 
10,000 IE/day is used for PTP in all patients with TBI, 
based on the possibility of a rapid reversal effect 
with protamine in case of need. Any progression of 
ICH after the initiation of PTP was identified through 
the review of head CTs both before and after initia-
tion of PTP by two experienced intensivists in ac-
cordance with the neuroradiologist. A CT scan after 
initiation of PTP was performed in the case of neu-
rological deterioration, defined as a decline in GCS 
≥ 2 or onset of a new motor deficit, or by absent 
neurological improvement. If the GCS assessment 
was not possible, such as in the case of sedated 
and intubated patients, a CT scan was usually per-
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formed. In the case of neurological improvement, 
a CT scan is usually planned in an out-patient clinic.
Statistical analysis
For descriptive statistics, categorical variables 
were expressed as absolute numbers with percent-
ages, normally distributed quantitative variables as 
mean ± standard deviation (SD) and non-normally 
distributed variables as median with interquartile 
range (IQR). 
In order to identify potential risk factors associ-
ated with VTE, we first performed a univariate logistic 
regression analysis considering VTE as the outcome 
variable (dependent variable). Odds ratios (ORs) were 
calculated and expressed with the corresponding 
95% confidence intervals (95% CI). With only 23 clini-
cally relevant episodes of VTE (events), we decided to 
insert no more than two independent variables into 
a multivariable logistic regression model, in order to 
keep the risk of overfitting low [30]. By more than 
two statistically significant independent variables 
identified by univariate analysis, we constructed all 
possible multivariable models as a combination of 
2 independent variables per model. Statistical signifi-
cance was set at P value < 0.05 for all analyses. Statis-
tical analysis was performed using Stata Version 12.1 
(StataCorp LP, College Station, TX, USA).
RESULTS
One hundred seventy-seven patients were in-
cluded in this study (Figure 1). Demographic and 
baseline characteristics of the study population are 
shown in Table 1. At the time of admission, 32 pa-
tients (18.1%) were being treated with anticoagulants 
or antiplatelet agents. Patients were stratified by the 
FIGURE 1. Flowchart of the study
TBI – traumatic brain injury, ICU – intensive care unit, GCS – Glasgow Coma Scale 
n = 994 patients with TBI admitted 
to the ICU during the study period
n = 177 patients included
Excluded (n = 817)
n = 543 pts with ICU-LOS < 48 h
n = 269 pts with GCS ≥ 13
n = 5 pts with incomplete datasets
TABLE 1. Baseline demographic data and severity scores of the study population
Parameter Overall 
(n = 177)
Patients with VTE 
(n =23)
Patients without VTE 
(n = 154)
P-value
Age, years 48 (29–67) 51 ± 20 50 ± 22 0.793
Male, n (%) 130 (73.4) 16 (69.6) 114 (74) 0.622
Hypoxemia, n (%) 44 (24.9) 38 (24.7) 6 (26.1) 1
Hypotension, n (%) 34 (19.2) 26 (16.9) 128 (83.1) 0.042
Pupillary reactivity, n (%)
 Normal 140 (79.1) 18 (78.3) 122 (79.2) 0.31
 Unilateral no reaction 12 (6.8) 2 (8.7) 10 (6.5)
 Bilateral no reaction 25 (14.1) 3 (13) 22 (14.3)
GCS m 3 (1–5) 4 (1–5) 3 (1–5) 0.83
AIS-head, n (%) 
1 29 (16.4) 2 (8.7) 27 (17.5) –
 2 28 (15.8) 6 (26.1) 22 (14.3)
 3 63 (35.6) 8 (34.8) 55 (35.7)
 4 57 (32.2) 7 (30.4) 50 (32.5)
 5 – – –
 6 – – –
ISS 21 (16–29) 27.1 ± 11.3 23 ± 12.6 0.144
SAPS II 46 ± 16 51 ± 13.3 44.9 ± 16.7 0.09
ICU-LOS, days 8 (3.7–14.5) 19.5 (6–27.7) 7.6 (3.5–13.1) 0.0005
MV-days 2.8 (1.2–4.8) 6.5 (2–9.2) 2.5 (1.2–4.4) 0.0006
ICU-mortality, n (%) 26 (15) 2 (8.7) 24 (15.6) 0.536
IVC filters, n (%) 12 (6.8) – – –
SCD, n (%) 158 (89.3) – – –
GCS m – motor component of Glasgow Coma Scale, AIS-head – abbreviated injury scale for head region, ISS – Injury Severity Score, SAPS II – Simplified Acute Physiology Score, ICU-LOS – length 
of stay at the intensive care unit, MV-days – number of days on mechanical ventilation, ICU-mortality – mortality in the intensive care unit, VTE – venous thromboembolism, IVC filters – inferior 
vena cava filters, SCD – sequential compression device. Data are expressed as median with interquartile range; frequency, or mean with standard deviation
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TABLE 3. Univariate logistic regression analysis considering venous thromboembo-
lism as the outcome variable
VTE OR 95% CI P-value
Hypotension (no as reference) 2.63 1.01–6.83 < 0.05
ICU-LOS (per day increase) 1.09 1.04–1.13 < 0.001
MV-days (per day increase) 1.25 1.11–1.41 < 0.001
PTP initiation (per day delay) 1.1 1.02–1.18 0.01
VTE – venous thromboembolism, ICU-LOS – length of stay at the intensive care unit, MV-days – number of days on 
mechanical ventilation, PTP – pharmacological VTE prophylaxis
TABLE 4. Multivariable models constructed with two independent variables per 
model
Model OR 95% CI P-value
1 Hypotension (no as reference)







2 Hypotension (no as reference)







3 Hypotension (no as reference)







4 ICU-LOS (per day increase) 







5 MV-days (per day increase) 







ICU-LOS – length of stay at the intensive care unit, MV-days – number of days on mechanical ventilation, PTP – phar-
macological venous thromboembolism prophylaxis
Marshall classification and numbers of patients per 
strata are provided in Table 2. Median time between 
TBI and initiation of PTP was 8 days (IQR 3–13).
A total of 23 clinically relevant episodes of VTE 
occurred (13%) during the hospitalization. On aver-
age, VTE was diagnosed on day 16.4 (± 11.2) after 
trauma. Demographic and baseline characteristics 
of patients who developed VTE (n = 23) did not 
differ from patients who did not, as presented in 
Table 1. However, patients who developed VTE had 
significantly more MV-days and longer ICU-LOS than 
patients who did not, as shown in Table 1. 
In the univariate logistic regression analysis 
(Table 3), hypotension in the pre-hospital setting, 
ICU-LOS, MV-days and delay of initiation of PTP were 
associated with the development of VTE. With four 
statistically significant independent variables, we 
could construct six different multivariable models. 
The different models (no more than 2 indepen-
dent variables per model) are presented in Table 4. 
The multivariable model containing MV-days and 
ICU-LOS is not displayed due to overfitting. PTP 
initiation is the only independent variable which 
remains statistically significant in the different mul-
tivariable logistic regression models.
Follow-up head CT scans after initiation of PTP 
were obtained from 65 (35.6%) patients. ICH pro-
gression was diagnosed in 7 (4%) patients and in 
3 of the them it led to a therapeutic change: intra-
cranial surgery (n = 2) and interruption of life-sus-
taining therapy (n = 1). 
Major bleeding complications after PTP initia-
tion other than ICH occurred in 5 patients (2.8%). 
Three of them (1.7%) had gastrointestinal bleed-
ing (two patients needed administration of blood 
products due to bleeding stomach ulcers, and one 
patient had retroperitoneal bleeding and needed 
surgery), and 2 (1.1%) patients bled from the respi-
ratory system (one patient had a hemothorax after 
cardiopulmonary resuscitation, and one patient pre-
sented massive hemoptysis after airway trauma due 
to malposition of a feeding tube).
DISCUSSION
The present study suggests that a delayed on-
set of PTP in patients with moderate to severe TBI 
is associated with an increased risk of developing 
VTE. This finding is of interest as the timing of PTP 
is one of the factors directly influenced by the at-
tending physician in the absence of internationally 
recognized recommendations. Furthermore, ICH 
progression after initiation of PTP in the study pop-
ulation was a rare event (4%) and only in very few 
patients (1.7%) did it initiate a therapeutic change, 
such as an operative intervention or interruption of 
life-sustaining therapies.
Because many events of VTE occur early after 
injury [31], any delay of onset of PTP could expose 
the patient to a major cause of secondary injury af-
ter trauma. On the other hand, due to the high risk 
of ICH progression in patients with TBI-induced co-
agulopathy, the time of initiation of PTP should be 
carefully evaluated. Currently, the time of initiation 
of PTP and the agent of choice for patients with TBI 
are widely variable due to insufficient evidence to 
support any recommendations. Therefore, timing, 
agent of choice, and dose of PTP are based on the 
physicians’ perceived risk for ICH progression. 
The Brain Trauma Foundation suggests either 
UFH or low-molecular-weight heparin (LMWH) be-
TABLE 2. Radiological findings on first brain computed tomography scan and 
Marshall classification
Parameter Overall, n = 177 (%)
Diffuse injury I 27 (15.3)
Diffuse injury II 62 (35)
Diffuse injury III 30 (16.9)
Diffuse injury IV 7 (4)
Evacuated mass lesion 40 (22.6)
Non-evacuated mass lesion 11 (6.2)
EDH 31 (17.5)
tSAH 31 (17.5)
EDH – epidural hemorrhage, tSAH – traumatic subarachnoid hemorrhage. Data are expressed as frequency
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cause both are efficacious [32]. A large, multicenter, 
retrospective study on trauma patients showed that 
LMWH was associated with a significantly lower rate 
of PEs compared to UFH [23]. On the other hand, 
UFH is more easily reversible and thus may be the 
preferred agent in the case of increased risk of hem-
orrhagic progression and if anesthesiological inter-
vention or surgery is at stake. For this reason, a con-
tinuous infusion of UFH is the preferred approach for 
patients with TBI at our institution. This approach, 
however, needs to be discussed critically after this 
analysis. The percentage of VTE observed in the study 
population was higher than in previous reports, with 
a delayed initiation of PTP being the only significant 
risk factor for VTE identified. Previous studies, in fact, 
described a lower rate of VTE after earlier administra-
tion of PTP [22, 33]. In these studies, however, also 
patients with mild TBI were included, while we con-
sidered patients with moderate to severe TBI only. 
In a similar population of patients with severe TBI, 
an even higher rate of VTE of 19% was reported [3]. 
In that study, however, and in contrast to our study, 
routine VTE screening was performed. Consequently, 
comparison of VTE prevalence data among studies is 
difficult due to the different severity of TBI and the 
different diagnostic VTE procedure. 
Overall, the frequency of relevant ICH progres-
sion after initiation of PTP was low. We are not able 
to distinguish whether this progression was a direct 
consequence of the initiation of PTP or indepen-
dent of the onset of PTP. In any case, a therapeutic 
impact, such as an operative intervention or inter-
ruption of life-sustaining therapy, was initiated in 
a very low proportion of patients, so the use of UFH 
seems to be safe in this context. In addition, Kwiatt 
found that ICH progression occurred with a simi-
lar frequency in patients who received PTP within 
48 hours after trauma, between 48 hours and seven 
days after trauma, and more than a week after trau-
ma, suggesting that the administration of PTP does 
not seem to change the natural course of TBI [19].
Our findings correspond to and complement the 
few previous studies in patients with moderate and 
severe head injury. In accordance with the report 
of Kim et al. [34], we support that UFH-based PTP 
is safe. However, we also confirm that efficiency of 
UFH-based PTP remains a concern, as we could not 
demonstrate a reduced incidence of VTE, compared 
to previous studies with different agents.
Preventing secondary brain injury in patients 
who are already at a high risk of death and disabil-
ity due to the primary injury should be the therapy 
goal of TBI management. So far, a standardized ap-
proach for PTP in patients with TBI does not exist. 
Our study has several limitations. Firstly, the ret-
rospective nature of our single-center experience 
limits the generalization of our results. Secondly, 
the initiation of PTP was an interdisciplinary con-
sensus of neurosurgeons, trauma surgeons and ICU 
physicians – but not based on a specific protocol. 
In fact, our results highlight the need for a critical 
discussion of our practice. It seems, in the decision-
making process regarding the initiation of PTP, that 
we tend to overestimate the risk of ICH progression 
and to underestimate the risk of VTE in patients with 
moderate and severe TBI. This leads to delayed PTP. 
Thirdly, the true incidence of VTE may be underesti-
mated in this study, because extremity ultrasonog-
raphy and CT scans were only performed in the case 
of clinical suspicion of VTE and not routinely. With 
only 23 events, we are not able to insert all relevant 
independent variables into the same multivariable 
logistic regression model. The small number of VTE 
events, in fact, precluded the inclusion in our final 
multivariable regression model of potentially inter-
esting additional variables. Furthermore, with only 
seven ICH progressions we were unable to build any 
predictive model of their occurrence. Fourthly, head 
CT scans to detect ICH progression after initiation 
of PTP were not performed systematically for all 
patients, but rather when clinically indicated in the 
case of neurological deterioration or if a neurologi-
cal improvement was not observed. Consequently, 
the rate of ICH progression may be underestimated. 
Finally, patients with moderate and severe TBI were 
analyzed together due to the small sample size, al-
though the risk of a VTE event and of TBI-related co-
agulopathy increases with the severity of TBI. 
As strengths of this study, we included all con-
secutive patients with moderate to severe TBI ad-
mitted to the ICU for at least 48 hours, thus protect-
ing against selection bias. In addition, differently 
from several previous studies, we considered only 
patients with moderate to severe TBI to better char-
acterize this specific population, which has a higher 
risk of VTE and ICH progression due to the sever-
ity of the injury, the immobilization, and the worse 
prognosis. Furthermore, despite the small number 
of VTE events reported, we constructed all possible 
“solid” multivariable models and we found in all of 
them that a delayed PTP initiation remains statisti-
cally significant. This finding encourages consider-
ing critically in the decision-making process regard-
ing the initiation of PTP the increased risk of VTE 
associated with a delayed initiation. 
A delayed onset of PTP exposes the patients 
with TBI to increased risk of VTE. The risk of ICH pro-
gression seems to be a major concern for initiation 
of PTP. Based on our data, it seems to be less threat-
ening than the risk of VTE. Due to the relevance of 
the topic and the lack of evidence to support any 
strategy for PTP, larger studies are required to ad-
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dress the timing, efficacy, safety, dose, and agent of 
choice for PTP in patients with TBI, ideally as ran-
domized controlled trials.
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